{"pmid":32501607,"title":"Selective C-reactive protein (CRP) apheresis for Covid-19 patients suffering from organ damage.","text":["Selective C-reactive protein (CRP) apheresis for Covid-19 patients suffering from organ damage.","Ther Apher Dial","Kayser, Stefan","Kunze, Rudolf","Sheriff, Ahmed","32501607"],"journal":"Ther Apher Dial","authors":["Kayser, Stefan","Kunze, Rudolf","Sheriff, Ahmed"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501607","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/1744-9987.13532","topics":["Mechanism","Treatment"],"weight":1,"_version_":1668890966467018752,"score":9.490897,"similar":[{"pmid":32450165,"title":"Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.","text":["Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.","Human coronaviruses, especially COVID-19, is an emerging pandemic infectious disease with high morbidity and mortality. Coronaviruses are associated with comorbidities, along with the symptoms of it. SARS-CoV-2 is one of the highly pathogenic coronaviruses that causes a high death rate compared to the SARS-CoV and MERS. In this review, we focused on the mechanism of coronavirus with comorbidities and impairment in multi-organ function. The main dysfunction upon coronavirus infection is damage to alveolar and acute respiratory failure. It is associated with the other organ damage such as cardiovascular risk via an increased level of hypertension through ACE2, gastrointestinal dysfunction, chronic kidney disease, diabetes mellitus, liver dysfunction, lung injury, CNS risk, ocular risks such as chemosis, conjunctivitis, and conjunctival hyperemia, cancer risk, venous thromboembolism, tuberculosis, aging, and cardiovascular dysfunction and reproductive risk. Along with this, we have discussed the immunopathology and coronaviruses at a molecular level and therapeutic approaches for the coronavirus infection. The comorbidities and multi-organ failure of COVID-19 have been explained at a molecular level along with the base of the SARS-CoV and MERS-CoV. This review would help us to understand the comorbidities associated with the coronaviruses with multi-organ damage.","Life Sci","KaviyarasiRenu","Prasanna, Pureti Lakshmi","Abilash, V G","32450165"],"abstract":["Human coronaviruses, especially COVID-19, is an emerging pandemic infectious disease with high morbidity and mortality. Coronaviruses are associated with comorbidities, along with the symptoms of it. SARS-CoV-2 is one of the highly pathogenic coronaviruses that causes a high death rate compared to the SARS-CoV and MERS. In this review, we focused on the mechanism of coronavirus with comorbidities and impairment in multi-organ function. The main dysfunction upon coronavirus infection is damage to alveolar and acute respiratory failure. It is associated with the other organ damage such as cardiovascular risk via an increased level of hypertension through ACE2, gastrointestinal dysfunction, chronic kidney disease, diabetes mellitus, liver dysfunction, lung injury, CNS risk, ocular risks such as chemosis, conjunctivitis, and conjunctival hyperemia, cancer risk, venous thromboembolism, tuberculosis, aging, and cardiovascular dysfunction and reproductive risk. Along with this, we have discussed the immunopathology and coronaviruses at a molecular level and therapeutic approaches for the coronavirus infection. The comorbidities and multi-organ failure of COVID-19 have been explained at a molecular level along with the base of the SARS-CoV and MERS-CoV. This review would help us to understand the comorbidities associated with the coronaviruses with multi-organ damage."],"journal":"Life Sci","authors":["KaviyarasiRenu","Prasanna, Pureti Lakshmi","Abilash, V G"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450165","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.lfs.2020.117839","keywords":["covid-19","comorbidities","multi-organ failure and immunopathology","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213891051520,"score":47.255768},{"pmid":32445579,"title":"Prognostic value of C-reactive protein in patients with COVID-19.","text":["Prognostic value of C-reactive protein in patients with COVID-19.","BACKGROUND: Elevated serum C-reactive protein (CRP) level was observed in most patients with COVID-19. METHODS: Data of COVID-19 patients with clinical outcome in a designated hospital in Wuhan, China, were retrospectively collected and analyzed from Jan 30 to Feb 20, 2020. The prognostic value of admission CRP was evaluated in patients with COVID-19. RESULTS: Out of 298 patients enrolled, 84 died and 214 recovered. Most non-survivors tended to be males, old aged, or with chronic diseases. Compared to survivors, non-survivors showed significantly elevated white blood cell and neutrophil count, neutrophil to lymphocyte ratio (NLR), systemic immune-inflammation index (SII, defined by platelet count multiply by NLR), CRP, procalcitonin, and D-dimer, and decreased red blood cell, lymphocyte, and platelet count. Age, neutrophil count, platelet count, and CRP were identified as independent predictors of adverse outcome. The area under the receiver operating characteristic (ROC) curve (AUC) of CRP (0.896) was significantly higher than that of age (0.833), neutrophil count (0.820), and platelet count (0.678) in outcome prediction (all p<0.05). With a cut-off value of 41.4, CRP exhibited sensitivity 90.5%, specificity 77.6%, positive predictive value 61.3%, and negative predictive value 95.4%. Subgroup analysis revealed that CRP remained robust accuracy in adverse outcome prediction in patients with different disease severity (AUC 0.832, z=10.23, p<0.001; AUC 0.989, z=44.04, p<0.001). CRP was also an independent discriminator of severe/critical illness on admission (AUC 0.783, z=10.69, p<0.001). CONCLUSIONS: In patients with COVID-19, admission CRP correlated with disease severity and tended to be a good predictor of adverse outcome.","Clin Infect Dis","Luo, Xiaomin","Zhou, Wei","Yan, Xiaojie","Guo, Tangxi","Wang, Benchao","Xia, Hongxia","Ye, Lu","Xiong, Jun","Jiang, Zongping","Liu, Yu","Zhang, Bicheng","Yang, Weize","32445579"],"abstract":["BACKGROUND: Elevated serum C-reactive protein (CRP) level was observed in most patients with COVID-19. METHODS: Data of COVID-19 patients with clinical outcome in a designated hospital in Wuhan, China, were retrospectively collected and analyzed from Jan 30 to Feb 20, 2020. The prognostic value of admission CRP was evaluated in patients with COVID-19. RESULTS: Out of 298 patients enrolled, 84 died and 214 recovered. Most non-survivors tended to be males, old aged, or with chronic diseases. Compared to survivors, non-survivors showed significantly elevated white blood cell and neutrophil count, neutrophil to lymphocyte ratio (NLR), systemic immune-inflammation index (SII, defined by platelet count multiply by NLR), CRP, procalcitonin, and D-dimer, and decreased red blood cell, lymphocyte, and platelet count. Age, neutrophil count, platelet count, and CRP were identified as independent predictors of adverse outcome. The area under the receiver operating characteristic (ROC) curve (AUC) of CRP (0.896) was significantly higher than that of age (0.833), neutrophil count (0.820), and platelet count (0.678) in outcome prediction (all p<0.05). With a cut-off value of 41.4, CRP exhibited sensitivity 90.5%, specificity 77.6%, positive predictive value 61.3%, and negative predictive value 95.4%. Subgroup analysis revealed that CRP remained robust accuracy in adverse outcome prediction in patients with different disease severity (AUC 0.832, z=10.23, p<0.001; AUC 0.989, z=44.04, p<0.001). CRP was also an independent discriminator of severe/critical illness on admission (AUC 0.783, z=10.69, p<0.001). CONCLUSIONS: In patients with COVID-19, admission CRP correlated with disease severity and tended to be a good predictor of adverse outcome."],"journal":"Clin Infect Dis","authors":["Luo, Xiaomin","Zhou, Wei","Yan, Xiaojie","Guo, Tangxi","Wang, Benchao","Xia, Hongxia","Ye, Lu","Xiong, Jun","Jiang, Zongping","Liu, Yu","Zhang, Bicheng","Yang, Weize"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445579","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/cid/ciaa641","keywords":["c-reactive protein","covid-2019","sars-cov-2","prognosis"],"locations":["Wuhan","China","neutrophil"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667600475934949376,"score":45.431084},{"pmid":32344321,"pmcid":"PMC7194648","title":"Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.","text":["Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.","BACKGROUND: The inflammatory response plays a critical role in coronavirus disease 2019 (COVID-19), and inflammatory cytokine storm increases the severity of COVID-19. OBJECTIVE: To investigate the ability of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT) to predict mild and severe cases of COVID-19. STUDY DESIGN: This retrospective cohort study included 140 patients diagnosed with COVID-19 from January 18, 2020, to March 12, 2020. The study population was divided into two groups according to disease severity: a mild group (MG) (n = 107) and a severe group (SG) (n = 33). Data on demographic characteristics, baseline clinical characteristics, and the levels of IL-6, CRP, and PCT on admission were collected. RESULTS: Among the 140 patients, the levels of IL-6, CRP, and PCT increased in 95 (67.9 %), 91 (65.0 %), and 8 (5.7 %) patients on admission, respectively. The proportion of patients with increased IL-6, CRP, and PCT levels was significantly higher in the SG than in the MG. Cox proportional hazard model showed that IL-6 and CRP could be used as independent factors to predict the severity of COVID-19. Furthermore, patients with IL-6 > 32.1 pg/mL or CRP > 41.8 mg/L were more likely to have severe complications. CONCLUSION: The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19.","J Clin Virol","Liu, Fang","Li, Lin","Xu, MengDa","Wu, Juan","Luo, Ding","Zhu, YuSi","Li, BiXi","Song, XiaoYang","Zhou, Xiang","32344321"],"abstract":["BACKGROUND: The inflammatory response plays a critical role in coronavirus disease 2019 (COVID-19), and inflammatory cytokine storm increases the severity of COVID-19. OBJECTIVE: To investigate the ability of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT) to predict mild and severe cases of COVID-19. STUDY DESIGN: This retrospective cohort study included 140 patients diagnosed with COVID-19 from January 18, 2020, to March 12, 2020. The study population was divided into two groups according to disease severity: a mild group (MG) (n = 107) and a severe group (SG) (n = 33). Data on demographic characteristics, baseline clinical characteristics, and the levels of IL-6, CRP, and PCT on admission were collected. RESULTS: Among the 140 patients, the levels of IL-6, CRP, and PCT increased in 95 (67.9 %), 91 (65.0 %), and 8 (5.7 %) patients on admission, respectively. The proportion of patients with increased IL-6, CRP, and PCT levels was significantly higher in the SG than in the MG. Cox proportional hazard model showed that IL-6 and CRP could be used as independent factors to predict the severity of COVID-19. Furthermore, patients with IL-6 > 32.1 pg/mL or CRP > 41.8 mg/L were more likely to have severe complications. CONCLUSION: The serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19."],"journal":"J Clin Virol","authors":["Liu, Fang","Li, Lin","Xu, MengDa","Wu, Juan","Luo, Ding","Zhu, YuSi","Li, BiXi","Song, XiaoYang","Zhou, Xiang"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344321","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jcv.2020.104370","keywords":["c-reactive protein","covid-19","interleukin-6","procalcitonin","prognosis"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495052152834,"score":41.52572},{"pmid":32320129,"title":"Explanation for COVID-19 infection neurological damage and reactivations.","text":["Explanation for COVID-19 infection neurological damage and reactivations.","Transbound Emerg Dis","Roe, Kevin","32320129"],"journal":"Transbound Emerg Dis","authors":["Roe, Kevin"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320129","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/tbed.13594","topics":["Diagnosis"],"weight":1,"_version_":1666138493665935362,"score":41.157413},{"pmid":32414383,"title":"Plasma CRP level is positively associated with the severity of COVID-19.","text":["Plasma CRP level is positively associated with the severity of COVID-19.","AIMS: The coronavirus disease 2019 (COVID-19) is characterized as highly contagious and deadly; however there is no credible and convenient biomarker to predict the severity of the disease. The aim of the present study was to estimate whether the CRP level is able to act as a marker in indicating the severity of COVID-19. METHODS: Patients who complained cough or chest pain with or without fever were enrolled after laboratory confirmed of SARS-CoV-2 viral nucleic acid via qRT-PCR. Chest computed tomography (CT) was then performed to classify the patients into mild, moderate and severe pneumonia groups according to the interim management guideline. Then linear regression models were applied to analyze the association between c-reactive protein (CRP) levels and severity of COVID-19 pneumonia. RESULTS: When compared to mild pneumonia, the adjusted-Odds Ratio were 11.46, p = 0.029 and 23.40, p = 0.025 in moderate and severe pneumonia, respectively. The area under receiver operation curve was 0.898 (95% CI 0.835, 0.962, p < 0.001). Higher plasma CRP level indicated severe COVID-19 pneumonia and longer inpatients duration. CONCLUSIONS: The level of plasma CRP was positively correlated to the severity of COVID-19 pneumonia. Our findings could assist to discern patients of moderate to severe COVID-19 pneumonia from the mild ones. Our findings may be useful as an earlier indicator for severe illness and help physicians to stratify patients for intense care unit transfer.","Ann Clin Microbiol Antimicrob","Chen, Wei","Zheng, Kenneth I","Liu, Saiduo","Yan, Zhihan","Xu, Chongyong","Qiao, Zengpei","32414383"],"abstract":["AIMS: The coronavirus disease 2019 (COVID-19) is characterized as highly contagious and deadly; however there is no credible and convenient biomarker to predict the severity of the disease. The aim of the present study was to estimate whether the CRP level is able to act as a marker in indicating the severity of COVID-19. METHODS: Patients who complained cough or chest pain with or without fever were enrolled after laboratory confirmed of SARS-CoV-2 viral nucleic acid via qRT-PCR. Chest computed tomography (CT) was then performed to classify the patients into mild, moderate and severe pneumonia groups according to the interim management guideline. Then linear regression models were applied to analyze the association between c-reactive protein (CRP) levels and severity of COVID-19 pneumonia. RESULTS: When compared to mild pneumonia, the adjusted-Odds Ratio were 11.46, p = 0.029 and 23.40, p = 0.025 in moderate and severe pneumonia, respectively. The area under receiver operation curve was 0.898 (95% CI 0.835, 0.962, p < 0.001). Higher plasma CRP level indicated severe COVID-19 pneumonia and longer inpatients duration. CONCLUSIONS: The level of plasma CRP was positively correlated to the severity of COVID-19 pneumonia. Our findings could assist to discern patients of moderate to severe COVID-19 pneumonia from the mild ones. Our findings may be useful as an earlier indicator for severe illness and help physicians to stratify patients for intense care unit transfer."],"journal":"Ann Clin Microbiol Antimicrob","authors":["Chen, Wei","Zheng, Kenneth I","Liu, Saiduo","Yan, Zhihan","Xu, Chongyong","Qiao, Zengpei"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414383","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s12941-020-00362-2","keywords":["crp","ct","pneumonia","sars-cov-2","severity"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666991242716643330,"score":40.366592}]}